<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03616366</url>
  </required_header>
  <id_info>
    <org_study_id>2017-I2M-1-009</org_study_id>
    <nct_id>NCT03616366</nct_id>
  </id_info>
  <brief_title>The Mechanism and Prognosis of Pulmonary Circulation Dysfunction</brief_title>
  <official_title>The Mechanism and Prognosis of Pulmonary Circulation Dysfunction in Pulmonary Injury and Recovery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Venous thromboembolism (VTE) is a condition which influenced by both environmental and
      genetic factors. This study is going to explore new significant Single nucleotide
      polymorphisms (SNPs) associated with VTE by Genome-Wide Association Studies (GWAS) and
      bioinformatics analysis. Transcriptomics and cytokine antibody array are also used to find
      new biomarkers of VTE's early diagnosis, severity and prognosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 10, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>All cause death</measure>
    <time_frame>6 months</time_frame>
    <description>death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Venous thromboembolism (VTE) recurrence</measure>
    <time_frame>6months</time_frame>
    <description>VTE recurrence detected by echocardiography or CTPA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chronic thromboembolism pulmonary hypertension(CTEPH)</measure>
    <time_frame>6 months</time_frame>
    <description>newly developed CTEPH detected by pulmonary angiography</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>VTE</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum and blood cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Acute VTE patients and healthy controls
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chinese Han population older than 14 years old

          -  Acute VTE patients diagnosed in 1 month

          -  With informed consent

        Exclusion Criteria:

          -  Patients with psychosis

          -  Patients with contraindications for computed tomographic pulmonary angiography (CTPA)

          -  Chronic VTE

          -  Recurrence of chronic VTE
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jianguo He, MD</last_name>
    <phone>80-10-88398060</phone>
    <email>hejianguofw@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cardiovascular Institute and Fu Wai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianguo He, MD</last_name>
      <phone>86 01088398060</phone>
      <email>hejianguofw@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianguo He, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>January 4, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>July 27, 2018</last_update_submitted>
  <last_update_submitted_qc>July 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Jianguo He</investigator_full_name>
    <investigator_title>Chief of Pulmonary Vascular Disease Center</investigator_title>
  </responsible_party>
  <keyword>VTE</keyword>
  <keyword>SNP</keyword>
  <keyword>biomarkers</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

